Skip to main content
2023 Financial Times Global Pharma and Biotech Summit
Tuesday, 7 November 2023 2:00 PM GMT

In-person

7 - 9 Nov.

14:00 GMT

2023 Financial Times Global Pharma and Biotech Summit

Driving Investment and Innovation in Life Sciences

Deloitte was a leading sponsor at the 2023 Financial Times Global Pharma and Biotech Summit, an industry-leading conference which brought together the world’s biggest pharma companies and other major organizations across the life sciences and health care value chain. The annual event is essential for you to stay on top of the latest trends and innovations in life sciences. CEOs, policymakers and thought leaders from around the world explored new frontiers for business and for health care and discussed what’s new in areas such as drug discovery, clinical trials, market access, and patient engagement.

Register now

While the world of life sciences is in a period of relentless disruption and advances in technology are transforming research and development, how are innovative treatments such as mRNA vaccines and cell therapies reshaping health care as we know it? How are companies overcoming the challenge of bringing products to market in an unsettled regulatory environment? As leaders across the pharma industry pursue growth for their companies, many disruptive forces are compelling them to radically transform business models. Technology and innovation are creating new avenues for growth, but the risks of investment are high. How are relations between pharma companies, suppliers, regulators, payers, doctors and patients evolving? Deloitte leaders, along with industry peers, unpacked many of these critical questions and more at this year’s conference.

Deloitte was proud to once again be a strategic sponsor to this year’s conference and offered a discounted registration.

Conference themes:

  • Investment: How is global disruption affecting investment in life sciences? Where are investors putting their money? What barriers to dealmaking are causing concern?
  • Innovation: How is artificial intelligence transforming drug discovery? What are the latest next-generation therapies? How are clinical trials evolving?
  • Leadership: How should pharma companies approach ESG? How are key pharma job functions evolving? What are CEOs doing to drive business transformation and growth?

Deloitte participation sessions

Economic uncertainty, geopolitical conflict, climate change, regulatory reform and other disruptive forces are impacting global industries including life sciences. How could the global economic outlook and policy decisions driven by it affect pharmaceutical sales across different markets and regions?

Panelists:

  • Ricardo Marek, President, Europe and Canada Business Unit, Takeda Pharmaceuticals
  • Emma Charles, Senior Vice President, Intercontinental Markets, Bristol Myers Squibb
  • Samantha Pearce, Senior Vice President, Europe and International, Jazz Pharmaceuticals
  • Julia Hoover, General Manager, UK and Ireland, Ferring Pharmaceuticals

Moderator: Greg Reh, Global Life Sciences & Health Care Industry Leader

The power of partnerships in life sciences is a positive legacy of the pandemic, but on a commercial level the M&A environment is still cautious. When can partnerships be an alternative to M&A and how is the value created?

Panelist:

  • Ryan Richardson, Chief Strategy Officer, BioNTech
  • Renée Aguiar-Lucander, CEO, Calliditas Therapeutics
  • Sean Breen, Head of Public-Private Partnerships and Global Science Policy, Takeda Pharmaceuticals

Moderator: Vicky Levy, Global Life Sciences Sector Leader

From clinical trials to consultations, technology is transforming patient engagement across health systems. How can companies engage with patients online without running foul of advertising restrictions?

Panelist:

  • Hanno Ronte, Partner, Monitor Deloitte
  • Richard Torbett, Chief Executive, Association of the British Pharmaceutical Industry
  • Harpreet Gill, Vice President, Decentralised Clinical Trials, ICON plc
  • Véronique Walsh, General Manager and Vice President, UK and Ireland, Gilead Sciences

On a global scale, economic uncertainty, geopolitical unrest and cyber-threats present evolving risks to supply chain stability. How can cloud services increase efficiency and resilience in pharma supply chains?

Panelists:

  • Matthew Winterman, SVP of Global Supply Chain and Strategy, AstraZenec
  • Stacy Malueg, Head of Supply Chain, US, Genentech

Moderator: Angela Bowden, Partner, Deloitte UK

How can a commitment to support health equity be aligned with commercial priorities? How are pharma companies addressing a historic lack of investment in women’s health?

Panelists:

  • Liz Hampson, Executive Director, Europe Deloitte Health Equity Institute
  • Fred Roeder, Managing Director, Consumer Choice Center
  • Jayasree K. Iyer, CEO, Access to Medicine Foundation
  • Seyda Atadan Memis, General Manager, UK and Ireland, Takeda Pharmaceuticals
  • Kimberly Smith, Senior Vice President, Head of Research and Development, ViiV Healthcare

 

Many pharma companies now claim to be making environmental, social and governance (ESG) a priority. What are some examples of changes in areas such as R&D, supply chains and commercialisation being made in pharma companies based on ESG goals?

Panelist:

  • Pinder Sahota, General Manager and Corporate Vice President, United Kingdom, Novo Nordisk
  • Amalia Adler-Waxman, Senior Vice President, Global Head of ESG and Head of Corporate Affairs, International Markets, Teva Pharmaceuticals
  • Marie-Andrée Gamache with Carrie Scott, Head, Sustainability and ESG Office, Novartis

Moderator: David Rakowski, Life Sciences & Health Care ESG Lead, Deloitte UK

Watch the session recordings here:

    Recommendations

    Global Health Equity Network Zero Health Gaps Pledge

    Deloitte is honored to be one of a growing list of 60+ signatories of the Zero Health Gaps Pledge, the first global, multi-sector, CEO-level pledge to help advance health equity. 
    Perspective
    5 minute read

    2023 Global Life Sciences Outlook

    The COVID-19 pandemic magnified the importance of digital advances as companies raced to meet the demand for new testing, vaccines, and treatments to combat the pandemic. However, with increased competition, a shifting regulatory landscape, and growing demands from patients and health care providers, life sciences companies face significant challenges and must find ways to differentiate themselves and remain competitive.
    Perspective
    2 minute read

    2024 Global Health Care Sector Outlook | Deloitte Global

    This annual report examines how the future of global health care is likely to be shaped by various trends such as, driving innovation, sustainability, social care integration, cost management, and workforce adaptation.
    Analysis
    5 minute read

    Measuring the return from pharmaceutical innovation 2022

    Our series of annual reports on Measuring the return from pharmaceutical innovation has provided insights into the state of biopharma R&D since 2010. We have expanded the analysis over time and our data set now covers the top 20 pharma companies by R&D spend. This year’s analysis demonstrates the step change we anticipated, in our 2021 report Nurturing growth, is yet to be realised.
    Analysis
    10 minute read